Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AstraZeneca AB v. Aurobindo Pharma Ltd. et al
Case Number:
1:14-cv-00664
Court:
Nature of Suit:
Judge:
Firms
- Eckert Seamans
- Faegre Drinker
- Heyman Enerio
- McCarter & English
- Morris James
- Phillips McLaughlin
- Potter Anderson
- Richards Layton
- Shaw Keller
- White and Williams
- Whiteford Taylor
- Young Conaway
Companies
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- AstraZeneca PLC
- Aurobindo Pharma Ltd.
- Glenmark Pharmaceuticals Ltd.
- Mylan NV
- Par Pharmaceutical Cos. Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Wockhardt Bio AG
- Wockhardt USA LLC
Sectors & Industries:
-
February 03, 2017
AstraZeneca Prevails In Trial Over Diabetes Drug Patent
A Delaware federal judge ruled Thursday that AstraZeneca's patents covering its $3.5 billion diabetes drugs Onglyza and Kombiglyze XR were not invalid for being obvious, though he denied the pharmaceutical company's request for attorneys' fees in its suit against generic drug makers.
-
September 20, 2016
AstraZeneca IP Suit Survives Generics Co.'s Application Swap
A Delaware federal judge has ruled that AstraZeneca's patent infringement suit against Wockhardt over planned generic versions of AstraZeneca diabetes drugs can proceed, even though Wockhardt last month told regulators it won't seek approval until the patent expires.